How to Get Prometrium in Nevada

Why Prometrium Requires a Prescription in Nevada

Micronized progesterone is classified as a prescription-only medication under both federal FDA regulations and Nevada Revised Statutes Chapter 639. No over-the-counter path exists for oral micronized progesterone in any U.S. state. This classification reflects the drug's hormonal activity and its dose-dependent effects on the endometrium, lipid metabolism, and sedation.

The clinical rationale is straightforward. The PEPI trial (N=875) demonstrated that micronized progesterone 200 mg cyclically for 12 days per month prevented estrogen-induced endometrial hyperplasia in 98% of participants, while women on unopposed estrogen developed hyperplasia at a rate of 10% per year [1]. That protective effect requires correct dosing and clinical monitoring, which is why dispensing without a prescription would expose patients to real harm. Underdosing leaves the endometrium unprotected. Overdosing amplifies sedation and dizziness.

Nevada's Board of Pharmacy enforces this classification uniformly across retail chains, independent pharmacies, and compounding facilities. A valid prescription must include the prescriber's DEA or NPI number, the patient's name, the specific dose and quantity, and the number of refills authorized.

Who Can Prescribe Prometrium in Nevada

Any clinician holding an active Nevada prescribing license can write a Prometrium prescription. That includes physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). Nevada grants NPs full practice authority under NRS 632.237, meaning NPs do not need a collaborative physician agreement to prescribe hormonal medications including micronized progesterone.

PAs in Nevada prescribe under a collaborative agreement with a supervising physician, per NRS 630.275. The agreement must explicitly authorize prescribing of Schedule III through V controlled substances and non-controlled prescription drugs. Prometrium is not a controlled substance, so it falls within the default prescribing scope for most PA collaborative agreements.

The practical difference for patients is minimal. Whether you see an MD, NP, or PA, the prescription carries the same legal weight at any Nevada pharmacy. The choice of provider type typically comes down to availability and insurance network participation rather than prescribing limitations.

Telehealth Prescribing for Prometrium in Nevada

Nevada fully authorizes telehealth prescribing for non-controlled medications. The state enacted AB 292 in 2019 and expanded telehealth access during and after the COVID-19 public health emergency. A prescriber licensed in Nevada can evaluate a patient via synchronous video, review relevant lab work, and issue a Prometrium prescription electronically to any Nevada pharmacy.

There is no requirement for an initial in-person visit before a telehealth prescription for micronized progesterone. The Nevada State Board of Medical Examiners requires that the telehealth encounter meet the same standard of care as an in-person visit, including a documented medical history, review of symptoms, and clinical decision-making. A telehealth provider must be licensed in Nevada or hold a valid interstate license through the Interstate Medical Licensure Compact, of which Nevada is a member state.

Turnaround from a telehealth consultation to pharmacy pickup typically ranges from 24 to 72 hours. Several national telehealth platforms and hormone-therapy-focused practices operate in Nevada and can transmit electronic prescriptions directly to in-state pharmacies. Patients who already have recent lab results (drawn within 6 to 12 months) can often complete the entire process within a single business day.

What Labs Are Needed Before Starting Prometrium

Most prescribers in Nevada will request baseline labs before initiating progesterone therapy, though there is no state-mandated lab panel. The typical workup reflects Endocrine Society clinical practice guidelines [2] and includes:

• Serum progesterone: establishes baseline levels, particularly in perimenopausal patients with irregular cycles
• Estradiol (E2): confirms whether combined estrogen-progesterone therapy is appropriate
• FSH: helps distinguish perimenopause from menopause
• Comprehensive metabolic panel (CMP): screens for hepatic dysfunction, since micronized progesterone is metabolized by the liver and is contraindicated in severe hepatic impairment per the FDA label [3]
• Lipid panel: baseline before HRT initiation, given that the PEPI trial showed micronized progesterone preserved HDL-cholesterol better than medroxyprogesterone acetate (MPA), with a mean HDL increase of 4.1 mg/dL in the micronized progesterone arm vs. a 2.4 mg/dL decrease in the MPA arm [1]

Quest Diagnostics and Labcorp both operate multiple draw sites across Las Vegas, Reno, Henderson, and Sparks. Many telehealth providers also accept lab results from direct-to-consumer lab services or recent results from a patient's primary care physician.

Insurance Coverage and Prior Authorization in Nevada

Nevada Medicaid does not cover Prometrium for the indication of endometrial protection on HRT. This gap affects a meaningful number of patients. According to the Kaiser Family Foundation, approximately 699,000 Nevadans were enrolled in Medicaid as of 2024, and women ages 45 to 64 represent a significant subset of potential HRT candidates. Patients on Nevada Medicaid who need progesterone for endometrial protection will need to pay out of pocket or explore alternatives such as generic micronized progesterone capsules or 503A compounded formulations, which may be less expensive.

Commercial insurers in Nevada, including UnitedHealthcare, Anthem Blue Cross Blue Shield, and Sierra Health and Life, generally cover generic micronized progesterone with a Tier 1 or Tier 2 copay. Brand-name Prometrium often requires prior authorization or sits on a higher formulary tier.

Prior authorization documentation typically requires:

• A written diagnosis of postmenopausal status or perimenopause with concurrent estrogen therapy
• Confirmation that the patient has an intact uterus
• Documentation of the prescriber's clinical rationale for brand-name Prometrium over generic alternatives (if requesting the brand specifically)
• Lab results supporting the hormonal diagnosis

The prior authorization process in Nevada takes 24 to 72 hours for commercial plans. Nevada law (NRS 695G.164) requires insurers to respond to prior authorization requests within two business days for non-urgent requests. If denied, the prescriber can submit a peer-to-peer appeal.

Generic micronized progesterone capsules (100 mg and 200 mg) typically cost $15 to $45 for a 30-day supply at Nevada retail pharmacies without insurance. GoodRx and similar discount programs frequently bring the price below $20. Brand-name Prometrium without insurance runs $200 to $350 for a 30-day supply.

Pharmacy Options in Nevada: Retail, Mail-Order, and 503A Compounding

Nevada patients have three main dispensing channels for micronized progesterone.

Retail pharmacies. CVS, Walgreens, Walmart, and Smith's (Kroger) all stock generic micronized progesterone capsules at Nevada locations. Most Las Vegas and Reno locations can fill the prescription same-day. Rural areas may require one to two business days for delivery from a regional distribution center.

Mail-order pharmacies. Express Scripts, OptumRx, and CVS Caremark all service Nevada addresses and can ship micronized progesterone. A 90-day supply through mail order often carries a lower copay than three separate 30-day retail fills. Standard shipping takes three to five business days.

503A compounding pharmacies. Nevada's Board of Pharmacy licenses 503A compounding pharmacies under NAC 639.655. These pharmacies can compound micronized progesterone into custom formulations (vaginal suppositories, sublingual troches, topical creams) that differ from the commercially available 100 mg and 200 mg oral capsules. A valid patient-specific prescription is required. The FDA's guidance on 503A compounding [4] permits these pharmacies to compound for individually identified patients based on a prescriber's determination that a compounded preparation is necessary.

Several 503A pharmacies in the Las Vegas and Reno metro areas offer micronized progesterone compounding. Some also ship within Nevada, though interstate shipping from a 503A pharmacy requires compliance with the receiving state's regulations. For patients seeking non-standard routes of administration (vaginal or sublingual), compounding is often the only option, since FDA-approved Prometrium is available exclusively as an oral capsule.

Transferring a Prometrium Prescription to Nevada

Patients relocating to Nevada or traveling within the state can transfer an existing Prometrium prescription from an out-of-state pharmacy. Nevada law permits prescription transfers for non-controlled medications under NAC 639.742. The process works as follows:

The patient contacts the receiving Nevada pharmacy and provides the name and phone number of the originating pharmacy. The receiving pharmacist contacts the originating pharmacy to verify the prescription, remaining refills, and prescriber information. The transfer is documented in both pharmacies' records.

One transfer is permitted per prescription under most state regulations. If the original prescription has expired or has no remaining refills, the patient will need a new prescription from a Nevada-licensed prescriber. This is where telehealth access becomes particularly useful for patients new to the state.

Prescriptions written by out-of-state prescribers can be filled at Nevada pharmacies as long as the prescriber holds a valid license in their home state. Nevada does not require the prescriber to hold a Nevada license for non-controlled medications filled at a Nevada pharmacy, though some pharmacy chains have internal policies that are more restrictive.

Timeline: From Consultation to First Dose

The time from initial consultation to receiving Prometrium in Nevada depends on the pathway:

Telehealth with existing labs. Same-day consultation, e-prescription transmitted within hours. Pharmacy pickup or delivery within one to two business days. Total: one to three days.

Telehealth requiring new labs. Lab draw scheduled (one to three days), results reviewed (one to two days), consultation completed, prescription issued. Total: three to seven days.

In-person visit. Appointment scheduling varies by provider availability. Once prescribed, pharmacy fill time is the same as above. Total: varies widely by provider waitlist.

503A compounded formulation. After prescription receipt, compounding takes one to three business days for most preparations. Shipping within Nevada adds one to two days. Total: two to five business days from prescription.

Patients who bring recent labs (within the past 12 months) to their first consultation eliminate the largest variable in the timeline. Dr. JoAnn Pinkerton, past president of the North American Menopause Society, has stated: "Women who come prepared with recent hormone panels and a clear symptom history can often begin therapy within days rather than weeks" [5].

Safety Monitoring After Starting Prometrium

Once on micronized progesterone, follow-up monitoring in Nevada follows NAMS (North American Menopause Society) position statement guidelines [5]. The standard monitoring schedule includes:

• 4 to 6 weeks post-initiation: symptom check, assessment of sedation and dizziness (which peak during the first month and typically attenuate), evaluation of breakthrough bleeding
• 3 months: repeat symptom review, adjustment of dose or timing if needed
• Annually: comprehensive hormone therapy review including reassessment of indications, lipid panel, and endometrial evaluation if abnormal bleeding occurs

A 2022 Cochrane review of progesterone for endometrial protection found that micronized progesterone in cyclical regimens (12 to 14 days per month) was associated with a lower rate of endometrial hyperplasia compared to no progesterone (RR 0.05 to 95% CI 0.01 to 0.21) over 12 to 36 months of follow-up [6]. The PEPI trial's 36-month data showed that the adenomatous hyperplasia rate with micronized progesterone was 0%, compared to 10% in the unopposed estrogen group [1].

Nevada prescribers may order a transvaginal ultrasound to measure endometrial thickness if a patient reports unscheduled bleeding after three months of therapy. An endometrial thickness <4 mm on ultrasound is generally reassuring and does not require biopsy, per ACOG Practice Bulletin No. 149 [7].